Products billed under this code include Breyanzi.
Payment limit per Up to 110 million CAR-positive viable T cells, per therapeutic dose, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Breyanzi | Juno Therapeutics, Inc. | 73153-0900-01 | 1 | $589,846.771 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $589,846.771 | +$10,276.157 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted September 17, 2026 |
| 3Q26 | $579,570.614 | +$17,309.778 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted September 15, 2026 |
| 2Q26 | $562,260.836 | +$59.594 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted September 15, 2026 |
| 1Q26 | $562,201.242 | −$336.943 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted September 15, 2026 |
| 4Q25 | $562,538.185 | +$20,902.528 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted September 8, 2026 |
| 3Q25 | $541,635.657 | +$25,193.372 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted March 10, 2026 |
| 2Q25 | $516,442.285 | −$43.682 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted March 10, 2026 |
| 1Q25 | $516,485.967 | −$240.109 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted December 19, 2025 |
| 4Q24 | $516,726.076 | +$20,335.871 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted June 11, 2025 |
| 3Q24 | $496,390.205 | +$22,329.585 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted June 11, 2025 |
| 2Q24 | $474,060.62 | +$207.104 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted March 11, 2025 |
| 1Q24 | $473,853.516 | +$395.09 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted December 19, 2024 |
| 4Q23 | $473,458.426 | +$18,969.116 | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted October 10, 2024 |
| 3Q23 | $454,489.31 | – | Up to 110 million CAR-positive viable T cells, per therapeutic dose | Lisocabtagene mara car pos t | v1, posted June 5, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
